ReviewFoods (Basel, Switzerland)2026
Allergenicity Assessment of Precision Fermentation-Derived Food Proteins.
Review in Foods (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Precision fermentation (PF) yields single, well-characterized recombinant proteins, such as dairy and egg white proteins, at an industrial scale, and several products have reached the market. Numerous PF-derived proteins, including ovomucoid and β-lactoglobulin, are known allergens designed as exact structural copies of their native homologs; hence, assessments center on equivalence rather than novel hazards. Therefore, the current tiered scheme of allergen database comparison, digestibility testing, and serum immunoglobulin E binding assays is applicable. Nevertheless, residual host cell proteins, altered host-dependent enzymatic glycosylation, and process-related impurities render PF-derived products imperfect replicas, and thermal and high-pressure processing, enzymatic hydrolysis, and non-enzymatic glycation can modify linear or conformational epitopes, thereby reducing IgE binding or generating neoepitopes. Because these effects depend on structural attributes acquired during production, including folding stability, disulfide bonding, glycosylation, and proteolytic resistance, PF-derived proteins and native proteins may respond differently to identical processing. This review explores the molecular attributes acquired at each stage of PF production and the epitope changes originating during processing, reevaluates the current assessment scheme, and outlines considerations for a premarket safety framework reflecting realistic processing and consumption conditions.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.